Multifunctional Spirocyclic Systems

New spiropyrans with different substituents in the benzopyran fragment have been synthesized and investigated. It was shown that introduction of aldehyde group in the structure of spiropyrans gives a possibility to obtain new functionalized compounds. Effects of the substituents on the photochromic behavior were studied

Onset of Perturbative Color Opacity at Small x and Upsilon Coherent Photoproduction off heavy nuclei at LHC

We study photon-induced coherent production of Upsilon in ultraperipheral heavy ion collisions at LHC and demonstrate that the counting rates will be sufficient to measure nuclear shadowing of generalized gluon distributions. This will establish the transition from the regime of color transparency to the regime of perturbative color opacity in an unambiguous way. We argue that such measurements will provide the possibility to investigate the interaction of ultra-small color dipoles with nuclei in QCD at large energies, which are beyond the reach of the electron-nucleon (nucleus) colliders, and will unambiguously discriminate between the leading twist and higher twist scenarios of gluon nuclear shadowing.Comment: 14 pages, 4 figure

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk